Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023).

IF 5.4 2区 医学 Q1 CHEMISTRY, MEDICINAL
Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI:10.1080/13543776.2024.2373771
Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi
{"title":"Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023).","authors":"Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi","doi":"10.1080/13543776.2024.2373771","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>COX-2 is a crucial enzyme in the manufacture of prostaglandins. The enzyme's metabolites might have an important function as regulators of the inflammatory response and other medical conditions such as cancer. Selective COX-2 inhibitors are believed to enhance or reverse the response of cancer chemotherapeutics.</p><p><strong>Areas covered: </strong>This study addresses the chemical structures as well as the antitumor activity of new COX-2 inhibitors produced in the recent five years, aiming to provide an insight into the mechanism of COX-2 induced PGE<sub>2</sub> powerful signal in cancer development.</p><p><strong>Expert opinion: </strong>The significance of selective COX-2 inhibitors as an efficient superfamily of compounds with anti-inflammatory, anti-Alzheimer's, anti-Parkinson's disease, and anticancer properties has piqued the passion of academics in the field of drug development. Long-term usage of selective COX-2 inhibitors, such as celecoxib has been proven in clinical trials to lower the incidence of several human malignancies. Furthermore, celecoxib has the potential to greatly increase the effectiveness of chemotherapy. Our extensive understanding of selective COX-2 inhibitor SAR may aid in the development of safer and more effective selective COX-2 inhibitors as cancer chemopreventive agents. This review focuses on the different structural classes of selective COX-2 inhibitors, with a particular emphasis on their SAR.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"733-757"},"PeriodicalIF":5.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2024.2373771","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: COX-2 is a crucial enzyme in the manufacture of prostaglandins. The enzyme's metabolites might have an important function as regulators of the inflammatory response and other medical conditions such as cancer. Selective COX-2 inhibitors are believed to enhance or reverse the response of cancer chemotherapeutics.

Areas covered: This study addresses the chemical structures as well as the antitumor activity of new COX-2 inhibitors produced in the recent five years, aiming to provide an insight into the mechanism of COX-2 induced PGE2 powerful signal in cancer development.

Expert opinion: The significance of selective COX-2 inhibitors as an efficient superfamily of compounds with anti-inflammatory, anti-Alzheimer's, anti-Parkinson's disease, and anticancer properties has piqued the passion of academics in the field of drug development. Long-term usage of selective COX-2 inhibitors, such as celecoxib has been proven in clinical trials to lower the incidence of several human malignancies. Furthermore, celecoxib has the potential to greatly increase the effectiveness of chemotherapy. Our extensive understanding of selective COX-2 inhibitor SAR may aid in the development of safer and more effective selective COX-2 inhibitors as cancer chemopreventive agents. This review focuses on the different structural classes of selective COX-2 inhibitors, with a particular emphasis on their SAR.

作为抗癌剂的选择性 COX-2 抑制剂:专利综述(2018-2023 年)。
简介COX-2 是制造前列腺素的关键酶。该酶的代谢产物可能具有调节炎症反应和癌症等其他疾病的重要功能。据信,选择性 COX-2 抑制剂可增强或逆转癌症化疗药物的反应:本研究探讨了近五年来产生的新型 COX-2 抑制剂的化学结构和抗肿瘤活性,旨在深入了解 COX-2 诱导 PGE2 强信号在癌症发展中的作用机制:选择性 COX-2 抑制剂作为具有抗炎、抗老年痴呆症、抗帕金森病和抗癌特性的高效化合物超家族,其重要意义激发了学术界在药物开发领域的热情。临床试验证明,长期使用选择性 COX-2 抑制剂(如塞来昔布)可降低多种人类恶性肿瘤的发病率。此外,塞来昔布还有可能大大提高化疗的效果。我们对选择性 COX-2 抑制剂 SAR 的广泛了解有助于开发更安全、更有效的选择性 COX-2 抑制剂作为癌症化学预防药物。本综述将重点介绍不同结构类别的选择性 COX-2 抑制剂,并特别强调其 SAR。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.10
自引率
1.50%
发文量
50
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信